Abstract
An estimated 40 million people live with human immunodeficiency virus (HIV) globally, and over four million people were newly diagnosed with HIV infection in 2006. Twenty-five million people have died as a result of HIV since its recognition in 1981. Where available, highly active antiretroviral therapy has resulted in significant decreases in HIV-associated morbidity and mortality. Nevertheless, opportunistic infections and conditions continue to occur, and their recognition and management continue to be an important component of HIV care.
MeSH terms
-
AIDS-Related Opportunistic Infections* / microbiology
-
AIDS-Related Opportunistic Infections* / therapy
-
Anti-HIV Agents / pharmacology
-
Anti-HIV Agents / therapeutic use*
-
Antiretroviral Therapy, Highly Active / adverse effects
-
CD4 Lymphocyte Count
-
HIV / drug effects
-
HIV Infections* / diagnosis
-
HIV Infections* / drug therapy
-
HIV Infections* / epidemiology
-
HIV Infections* / immunology
-
Humans
-
Immune Reconstitution Inflammatory Syndrome / diagnosis
-
Immune Reconstitution Inflammatory Syndrome / etiology
-
Immune Reconstitution Inflammatory Syndrome / prevention & control
-
Practice Guidelines as Topic
-
Viral Load